Ovid Therapeutics OVID Cash Flow Statement (2016-2026)

NASDAQ OVID
$2.80 +0.02 (+0.72%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

Ovid Therapeutics Quarterly Cash Flow Statement

Periods 42 quarters
Latest Jun 2026

Ovid Therapeutics reported cash from operations of -$17.60M and free cash flow of -$17.60M for the quarter ended Jun 2026, down 268.7% year over year. This cash flow statement covers 42 quarters of results from Mar 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-11.38M-26.00M-16.11M-14.59M-11.97M-11.50M-13.36M-12.41M-11.25M-15.32M-11.69M8.52M-14.01M-9.25M-10.23M-4.68M-12.16M9.66M-16.99M-15.01M
Share-based CompensationStock Comp.
10.68M1.32M15.78M0.01M1.92M1.95M1.63M1.79M1.97M1.74M1.31M1.26M1.28M1.22M1.11M1.20M1.05M1.43M
Deferred Taxes
Cash from OperationsCash from Ops.
-10.87M-12.00M-20.09M-13.29M-12.68M-9.18M-12.11M-11.71M-10.05M-11.91M-16.69M-14.26M-15.01M-10.01M-10.28M-4.77M-12.87M-10.41M-13.90M-17.60M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.35M0.26M0.25M0.25M0.26M0.26M0.26M0.27M0.27M0.28M0.28M0.29M0.29M0.30M0.30M0.31M0.32M
Depreciation & Amortization (CF)Dep. & Amort.
0.05M0.06M0.07M0.10M0.16M0.18M0.14M0.14M0.15M0.14M0.14M0.15M0.17M0.16M0.14M0.10M0.02M0.02M0.04M0.02M
Change in Working Capital
Change in Account PayablesChange Payables
2.09M-4.87M2.36M-3.58M0.92M-0.12M1.93M-2.55M2.49M-0.11M1.12M-2.01M0.48M-1.24M2.00M-2.24M0.25M3.62M-1.51M
Change in Accured ExpensesChange Accured Exp.
-3.43M0.75M0.30M-3.37M1.10M-1.19M-0.42M1.35M0.79M0.30M-2.49M4.07M-0.54M-1.58M-0.00M-3.15M0.03M2.05M-1.40M-0.35M
Investing Activities
Capital ExpendituresCapex
0.01M0.16M0.05M1.04M0.02M0.12M0.01M0.10M-0.01M0.02M0.10M-0.03M
Change in Acquisitions & DivestmentsChange Acquisitions
30.00M60.00M40.00M45.00M25.00M10.00M30.00M50.00M10.00M38.00M10.00M17.00M10.00M5.00M10.00M16.00M
Cash from Investing ActivitiesCash from Investing
-0.06M-0.16M-1.08M-80.68M-1.96M-4.17M30.23M20.07M-4.36M-48.52M20.19M12.82M0.29M21.29M5.10M12.05M5.05M-72.06M5.95M-86.74M
Financing Activities
Other financing activitiesOther financing
0.46M0.31M0.03M0.11M0.08M-0.04M0.07M0.21M0.22M0.03M0.23M0.36M0.04M0.01M0.01M75.09M59.80M-3.62M
Cash from Financing ActivitiesCash from Financing
0.55M0.11M0.03M0.11M0.08M-0.04M0.07M0.21M0.22M30.03M0.23M0.36M0.04M0.01M0.01M75.18M88.98M21.60M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
2.05M2.43M
Net Equity Issued and RepurchasedNet Equity Issued
0.02M2.37M0.00M
Additional items
Exchange Rate EffectFX Effect
-0.12M-0.00M
Change in Cash
-10.39M-12.05M-21.13M-93.86M-14.56M-13.39M18.18M8.57M-14.19M-30.39M3.73M-1.08M-14.68M11.28M-5.17M7.28M-7.80M-7.46M80.91M-82.74M
Free Cash FlowFCF
-10.88M-12.16M-20.13M-14.33M-12.69M-9.30M-12.13M-11.80M-10.05M-11.90M-16.70M-14.35M-15.01M-9.98M-10.28M-4.77M-12.87M-10.41M-13.90M-17.60M
Net Cash FlowNCF
-10.39M-12.05M-21.13M-93.86M-14.56M-13.39M18.18M8.57M-14.19M-30.39M3.73M-1.08M-14.68M11.28M-5.17M7.28M-7.80M-7.29M81.03M-82.74M